Stem cell-based therapies for sepsis

Anesthesiology

Volumn 127, Issue 6, 2017, Pages 1017-1034

  Keane, Colm ^a   Jerkic, Mirjana ^b   Laffey, John G ^a,b,c  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLAMMASOME;

ADAPTIVE IMMUNITY; CELL CONTACT; CELL HETEROGENEITY; CELL POPULATION; CLINICAL EFFECTIVENESS; DISEASE CLASSIFICATION; EXOSOME; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LUNG INFECTION; MACROPHAGE; MESENCHYMAL STEM CELL TRANSPLANTATION; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; STEM CELL TRANSPLANTATION; VIRUS INFECTION; ANIMAL; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; PROCEDURES; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, CELLULAR; SEPSIS; STEM CELL TRANSPLANTATION;

EID: 85037556162     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000001882     Document Type: Review

References (158)

1. Gotts JE, Matthay MA: Sepsis: Pathophysiology and clinical management. BMJ 2016; 353:i1585
2. Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med 2013; 369:840-51
3. van der Poll T, Opal SM: Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8:32-43
4. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K; EPIC II Group of Investigators: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-9
5. Vincent JL, Marshall JC, Namendys-Silva SA, François B, Martin-Loeches I, Lipman J, Reinhart K, Antonelli M, Pickkers P, Njimi H, Jimenez E, Sakr Y; ICON Investigators: Assessment of the worldwide burden of critical illness: The intensive care over nations (ICON) audit. Lancet Respir Med 2014; 2:380-6
6. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC, Reinhart K; International Forum of Acute Care Trialists: Assessment of global incidence and mortality of hospital-treated sepsis: Current estimates and limitations. Am J Respir Crit Care Med 2016; 193:259-72
7. Torio CM, Andrews RM: National inpatient hospital costs: The most expensive conditions by payer, 2011. Statistical Brief #160. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, Agency for Healthcare Research and Quality, 2013
8. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-54
9. Iwashyna TJ, Cooke CR, Wunsch H, Kahn JM: Population burden of long-term survivorship after severe sepsis in older Americans. J Am Geriatr Soc 2012; 60:1070-7
10. Gaieski DF, Edwards JM, Kallan MJ, Carr BG: Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 2013; 41:1167-74
11. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637
12. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R: Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014; 311:1308-16
13. Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, Iwashyna TJ: Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA 2014; 312:90-2
14. Beck MK, Jensen AB, Nielsen AB, Perner A, Moseley PL, Brunak S: Diagnosis trajectories of prior multi-morbidity predict sepsis mortality. Sci Rep 2016; 6:36624
15. Iwashyna TJ, Ely EW, Smith DM, Langa KM: Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010; 304:1787-94
16. Hotchkiss RS, Monneret G, Payen D: Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013; 13:862-74
17. Pisetsky DS: The origin and properties of extracellular DNA: From PAMP to DAMP. Clin Immunol 2012; 144:32-40
18. Boomer JS, Green JM, Hotchkiss RS: The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer?. Virulence 2014; 5:45-56
19. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-50
20. Kumar A, Kethireddy S: Emerging concepts in optimizing antimicrobial therapy of septic shock: Speed is life but a hammer helps too. Crit Care 2013; 17:104
21. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306:2594-605
22. Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, Carcillo JA: Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med 2011; 37:525-32
23. Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, Bauer M, Riedemann NC: The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011; 15:R183
24. Walton AH, Muenzer JT, Rasche D, Boomer JS, Sato B, Brownstein BH, Pachot A, Brooks TL, Deych E, Shannon WD, Green JM, Storch GA, Hotchkiss RS: Reactivation of multiple viruses in patients with sepsis. PLoS One 2014; 9:e98819
25. van Vught LA, Klein Klouwenberg PM, Spitoni C, Scicluna BP, Wiewel MA, Horn J, Schultz MJ, Nürnberg P, Bonten MJ, Cremer OL, van der Poll T; MARS Consortium: Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 2016; 315:1469-79
26. Angus DC: The search for effective therapy for sepsis: Back to the drawing board?. JAMA 2011; 306:2614-5
27. Cohen J, Opal S, Calandra T: Sepsis studies need new direction. Lancet Infect Dis 2012; 12:503-5
28. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ Jr: Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23:1430-9
29. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk HD: Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: A double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180:640-8
30. Bellingan G, Maksimow M, Howell DC, Stotz M, Beale R, Beatty M, Walsh T, Binning A, Davidson A, Kuper M, Shah S, Cooper J, Waris M, Yegutkin GG, Jalkanen J, Salmi M, Piippo I, Jalkanen M, Montgomery H, Jalkanen S: The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: An open-label study. Lancet Respir Med 2014; 2:98-107
31. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA; NHLBI ARDS Network: Subphenotypes in acute respiratory distress syndrome: Latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014; 2:611-20
32. Curley GF, Hayes M, Ansari B, Shaw G, Ryan A, Barry F, O'Brien T, O'Toole D, Laffey JG: Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax 2012; 67:496-501
33. Curley GF, Ansari B, Hayes M, Devaney J, Masterson C, Ryan A, Barry F, O'Brien T, Toole DO, Laffey JG: Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury. ANESTHESIOLOGY 2013; 118:924-32
34. Hayes M, Masterson C, Devaney J, Barry F, Elliman S, O'Brien T, O'Toole D, Curley GF, Laffey JG: Therapeutic efficacy of human mesenchymal stromal cells in the repair of established ventilator-induced lung injury in the rat. ANESTHESIOLOGY 2015; 122:363-73
35. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC, Stewart DJ: Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010; 182:1047-57
36. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, Matthay MA: Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010; 28:2229-38
37. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA: Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179:1855-63
38. Lee JW FX, Gupta N, Serikov V, Matthay MA: Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA 2009; 106:6
39. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA: Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial. Lancet Respir Med 2015; 3:24-32
40. Zhu YG FX, Abbott J, Fang XH, Hao Q, Monsel A, Qu JM, Matthay MA, Lee JW: Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxininduced acute lung injury in mice. Stem Cells 2014; 32:10
41. Hao Q ZY, Monsel A, Gennai S, Lee T, Xu F, Lee JW: Study of bone marrow and embryonic stem cell-derived human mesenchymal stem cells for treatment of escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells Transl Med 2015; 4:9
42. Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, Rowlands DJ, Quadri SK, Bhattacharya S, Bhattacharya J: Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012; 18:759-65
43. Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V, Matthay MA: Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012; 67:533-9
44. Devaney J, Horie S, Masterson C, Elliman S, Barry F, O'Brien T, Curley GF, O'Toole D, Laffey JG: Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax 2015; 70:625-35
45. Shalaby SM, El-Shal AS, Abd-Allah SH, Selim AO, Selim SA, Gouda ZA, Abd El Motteleb DM, Zanfaly HE, El-Assar HM, Abdelazim S: Mesenchymal stromal cell injection protects against oxidative stress in Escherichia coli-induced acute lung injury in mice. Cytotherapy 2014; 16:764-75
46. Hackstein H, Lippitsch A, Krug P, Schevtschenko I, Kranz S, Hecker M, Dietert K, Gruber AD, Bein G, Brendel C, Baal N: Prospectively defined murine mesenchymal stem cells inhibit Klebsiella pneumoniae-induced acute lung injury and improve pneumonia survival. Respir Res 2015; 16:123
47. Mao YX, Xu JF, Seeley EJ, Tang XD, Xu LL, Zhu YG, Song YL, Qu JM: Adipose tissue-derived mesenchymal stem cells attenuate pulmonary infection caused by pseudomonas aeruginosa via inhibiting overproduction of prostaglandin E2. Stem Cells 2015; 33:2331-42
48. Sutton MT, Fletcher D, Ghosh SK, Weinberg A, van Heeckeren R, Kaur S, Sadeghi Z, Hijaz A, Reese J, Lazarus HM, Lennon DP, Caplan AI, Bonfield TL: Antimicrobial properties of mesenchymal stem cells: Therapeutic potential for cystic fibrosis infection, and treatment. Stem Cells Int 2016; 2016:5303048
49. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW, Gupta N, Petrini M, Matthay MA: Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012; 302:L1003-13
50. Curley GF, M. J, Dixon S, Hogan G, Masterson C, O'Toole D, Devaney J, Laffey JG: Cryopreserved, xeno-free human umbilical cord mesenchymal stromal cells reduce lung injury severity and bacterial burden in rodent E. coli induced acute respiratory distress syndrome. Crit Care Med 2017; 45:e202-12
51. Kim ES, Chang YS, Choi SJ, Kim JK, Yoo HS, Ahn SY, Sung DK, Kim SY, Park YR, Park WS: Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli-induced acute lung injury in mice. Respir Res 2011; 12:108
52. Asmussen S, Ito H, Traber DL, Lee JW, Cox RA, Hawkins HK, McAuley DF, McKenna DH, Traber LD, Zhuo H, Wilson J, Herndon DN, Prough DS, Liu KD, Matthay MA, Enkhbaatar P: Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax 2014; 69:819-25
53. Monsel A, Zhu YG, Gennai S, Hao Q, Hu S, Rouby JJ, Rosenzwajg M, Matthay MA, Lee JW: Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am J Respir Crit Care Med 2015; 192:324-36
54. Yuan Y, Lin S, Guo N, Zhao C, Shen S, Bu X, Ye H: Marrow mesenchymal stromal cells reduce methicillin-resistant Staphylococcus aureus infection in rat models. Cytotherapy 2014; 16:56-63
55. Mot YY, Othman I, Sharifah SH: Synergistic antibacterial effect of co-administering adipose-derived mesenchymal stromal cells and Ophiophagus hannah L-amino acid oxidase in a mouse model of methicillin-resistant Staphylococcus aureus-infected wounds. Stem Cell Res Ther 2017; 8:5
56. Guerra AD, Cantu DA, Vecchi JT, Rose WE, Hematti P, Kao WJ: Mesenchymal stromal/stem cell and minocycline-loaded hydrogels inhibit the growth of staphylococcus aureus that evades immunomodulation of blood-derived leukocytes. AAPS J 2015; 17:620-30
57. Shin S, Kim Y, Jeong S, Hong S, Kim I, Lee W, Choi S: The therapeutic effect of human adult stem cells derived from adipose tissue in endotoxemic rat model. Int J Med Sci 2013; 10: 11
58. Hu Y QC, Zheng G, Lai D, Tao H, Zhang Y, Qiu G, Ge M, Huang L, Chen L, Cheng B, Shu Q, Xu J: Mesenchymal stem cell-educated macrophages ameliorate LPS-induced systemic response. Mediators Inflamm 2016; 2016:13
59. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E: Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15:42-9
60. Luo CJ, Zhang FJ, Zhang L, Geng YQ, Li QG, Hong Q, Fu B, Zhu F, Cui SY, Feng Z, Sun XF, Chen XM: Mesenchymal stem cells ameliorate sepsis-associated acute kidney injury in mice. Shock 2014; 41:123-9
61. Hall SR, Tsoyi K, Ith B, Padera RF Jr, Lederer JA, Wang Z, Liu X, Perrella MA: Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: The importance of neutrophils. Stem Cells 2013; 31:397-407
62. dos Santos CC, Murthy S, Hu P, Shan Y, Haitsma JJ, Mei SH, Stewart DJ, Liles WC: Network analysis of transcriptional responses induced by mesenchymal stem cell treatment of experimental sepsis. Am J Pathol 2012; 181:1681-92
63. Kim H, Darwish I, Monroy MF, Prockop DJ, Liles WC, Kain KC: Mesenchymal stromal (stem) cells suppress pro-inflammatory cytokine production but fail to improve survival in experimental staphylococcal toxic shock syndrome. BMC Immunol 2014; 15:1
64. Hong J HA, Wang L, Schmitt A, Wuchter P, Tabarkiewicz J, Kleist C, Bieback K, Ho AD, Schmitt M.: Indoleamine 2, 3-dioxygenase mediates inhibition of virus- specific CD8(+) T cell proliferation by human mesenchymal stromal cells. Cytotherapy 2016; 18:9
65. Meisel R BS, Heseler K, Degistirici O, Bülle H, Woite C, Stuhlsatz S, Schwippert W, Jäger M, Sorg R, Henschler R, Seissler J, Dilloo D, Däubener W: Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2, 3-dioxygenase. Leukemia 2011; 25:7
66. Gotts JE, Abbott J, Matthay MA: Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy. Am J Physiol Lung Cell Mol Physiol 2014; 307:L395-406
67. Darwish I, Banner D, Mubareka S, Kim H, Besla R, Kelvin DJ, Kain KC, Liles WC: Mesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza. PLoS One 2013; 8:e71761
68. Li Y, Xu J, Shi W, Chen C, Shao Y, Zhu L, Lu W, Han X: Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther 2016; 7:159
69. Fan H, Wong D, Ashton SH, Borg KT, Halushka PV, Cook JA: Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation 2012; 35:130-7
70. Weil BR, Herrmann JL, Abarbanell AM, Manukyan MC, Poynter JA, Meldrum DR: Intravenous infusion of mesenchymal stem cells is associated with improved myocardial function during endotoxemia. Shock 2011; 36:235-41
71. Chao YH, Wu HP, Wu KH, Tsai YG, Peng CT, Lin KC, Chao WR, Lee MS, Fu YC: An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis. PLoS One 2014; 9:e110338
72. Zullo JA, Nadel EP, Rabadi MM, Baskind MJ, Rajdev MA, Demaree CM, Vasko R, Chugh SS, Lamba R, Goligorsky MS, Ratliff BB: The secretome of hydrogel-coembedded endothelial progenitor cells and mesenchymal stem cells instructs macrophage polarization in endotoxemia. Stem Cells Transl Med 2015; 4:852-61
73. Cóndor JM, Rodrigues CE, Sousa Moreira Rd, Canale D, Volpini RA, Shimizu MH, Camara NO, Noronha Ide L, Andrade L: Treatment with human Wharton's jelly-derived mesenchymal stem cells attenuates sepsis-induced kidney injury, liver injury, and endothelial dysfunction. Stem Cells Transl Med 2016; 5:1048-57
74. Li N, Hu DH, Wang YJ, Hu XL, Zhang Y, Li XQ, Shi JH, Bai XZ, Cai WX: Effects of adipose-derived stem cells on renal injury in burn mice with sepsis [in Chinese]. Zhonghua Shao Shang Za Zhi 2013; 29:249-54
75. Weil BR, Manukyan MC, Herrmann JL, Wang Y, Abarbanell AM, Poynter JA, Meldrum DR: Mesenchymal stem cells attenuate myocardial functional depression and reduce systemic and myocardial inflammation during endotoxemia. Surgery 2010; 148:444-52
76. Sung PH, Chang CL, Tsai TH, Chang LT, Leu S, Chen YL, Yang CC, Chua S, Yeh KH, Chai HT, Chang HW, Chen HH, Yip HK: Apoptotic adipose-derived mesenchymal stem cell therapy protects against lung and kidney injury in sepsis syndrome caused by cecal ligation puncture in rats. Stem Cell Res Ther 2013; 4:155
77. Chen HH, Chang CL, Lin KC, Sung PH, Chai HT, Zhen YY, Chen YC, Wu YC, Leu S, Tsai TH, Chen CH, Chang HW, Yip HK: Melatonin augments apoptotic adipose-derived mesenchymal stem cell treatment against sepsis-induced acute lung injury. Am J Transl Res 2014; 6:439-58
78. Ou H, Zhao S, Peng Y, Xiao X, Wang Q, Liu H, Xiao X, Yang M: Comparison of bone marrow tissue- and adipose tissuederived mesenchymal stem cells in the treatment of sepsis in a murine model of lipopolysaccharide-induced sepsis. Mol Med Rep 2016; 14:3862-70
79. Danchuk S, Ylostalo JH, Hossain F, Sorge R, Ramsey A, Bonvillain RW, Lasky JA, Bunnell BA, Welsh DA, Prockop DJ, Sullivan DE: Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6. Stem Cell Res Ther 2011; 2:27
80. Letourneau PA, Menge TD, Wataha KA, Wade CE, S Cox C Jr, Holcomb JB, Pati S: Human bone marrow derived mesenchymal stem cells regulate leukocyte-endothelial interactions and activation of transcription factor NF-kappa B. J Tissue Sci Eng 2011; suppl 3:001
81. Miao CM, Jiang XW, He K, Li PZ, Liu ZJ, Cao D, Ou ZB, Gong JP, Liu CA, Cheng Y: Bone marrow stromal cells attenuate LPS-induced mouse acute liver injury via the prostaglandin E 2-dependent repression of the NLRP3 inflammasome in Kupffer cells. Immunol Lett 2016; 179:102-13
82. Martinon F, Burns K, Tschopp J: The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10:417-26
83. Kolaczkowska E, Kubes P: Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13:159-75
84. Sônego F, Castanheira FV, Ferreira RG, Kanashiro A, Leite CA, Nascimento DC, Colón DF, Borges Vde F, Alves-Filho JC, Cunha FQ: Paradoxical roles of the neutrophil in sepsis: Protective and deleterious. Front Immunol 2016; 7:155
85. Nourshargh S, Renshaw SA, Imhof BA: Reverse migration of neutrophils: Where, when, how, and why?. Trends Immunol 2016; 37:273-86
86. McAvoy EF, McDonald B, Parsons SA, Wong CH, Landmann R, Kubes P: The role of CD14 in neutrophil recruitment within the liver microcirculation during endotoxemia. J Immunol 2011; 186:2592-601
87. Wei J, Wei C, Wang M, Qiu X, Li Y, Yuan Y, Jin C, Leng L, Wang J, Yang X, He F: The GTPase-activating protein GIT2 protects against colitis by negatively regulating Toll-like receptor signaling. 2014; 111:8883-8
88. Elman JS, Li M, Wang F, Gimble JM, Parekkadan B: A comparison of adipose and bone marrow-derived mesenchymal stromal cell secreted factors in the treatment of systemic inflammation. J Inflamm (Lond) 2014; 11:1
89. Zhao X, Liu D, Gong W, Zhao G, Liu L, Yang L, Hou Y: The tolllike receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143. Stem Cells 2014; 32:521-33
90. Glass CK, Natoli G: Molecular control of activation and priming in macrophages. Nat Immunol 2016; 17:26-33
91. Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK: New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat Immunol 2016; 17:34-40
92. Luz-Crawford P, Jorgensen C, Djouad F: Mesenchymal stem cells direct the immunological fate of macrophages. Results Probl Cell Differ 2017; 62:61-72
93. Kim J, Hematti P: Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages. Exp Hematol 2009; 37:1445-53
94. Brekke OL, Christiansen D, Fure H, Fung M, Mollnes TE: The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J Leukoc Biol 2007; 81:1404-13
95. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA: Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013; 187:751-60
96. Jackson MV, Morrison TJ, Doherty DF, McAuley DF, Matthay MA, Kissenpfennig A, O'Kane CM, Krasnodembskaya AD: Mitochondrial transfer via tunneling nanotubes is an important mechanism by which mesenchymal stem cells enhance macrophage phagocytosis in the in vitro and in vivo models of ARDS. Stem Cells 2016; 34:2210-23
97. Li B, Zhang H, Zeng M, He W, Li M, Huang X, Deng DY, Wu J: Bone marrow mesenchymal stem cells protect alveolar macrophages from lipopolysaccharide-induced apoptosis partially by inhibiting the Wnt/β-catenin pathway. Cell Biol Int 2015; 39:192-200
98. Dal-Secco D, Wang J, Zeng Z, Kolaczkowska E, Wong CH, Petri B, Ransohoff RM, Charo IF, Jenne CN, Kubes P: A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+ monocytes at a site of sterile injury. J Exp Med 2015; 212:447-56
99. Duffy MM, Ritter T, Ceredig R, Griffin MD: Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2:34
100. Ghannam S, Pène J, Moquet-Torcy G, Torcy-Moquet G, Jorgensen C, Yssel H: Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010; 185:302-12
101. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F: Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24:386-98
102. DelaRosa O, Sánchez-Correa B, Morgado S, Ramírez C, del Río B, Menta R, Lombardo E, Tarazona R, Casado JG: Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killermediated lysis. Stem Cells Dev 2012; 21:1333-43
103. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99:3838-43
104. Belkaid Y, Tarbell K: Regulatory T cells in the control of host-microorganism interactions. Annu Rev Immunol 2009; 27:551-89
105. Sun J, Han ZB, Liao W, Yang SG, Yang Z, Yu J, Meng L, Wu R, Han ZC: Intrapulmonary delivery of human umbilical cord mesenchymal stem cells attenuates acute lung injury by expanding CD4+CD25+ Forkhead Boxp3 (FOXP3)+ regulatory T cells and balancing anti- and pro-inflammatory factors. Cell Physiol Biochem 2011; 27:587-96
106. Heuer JG, Zhang T, Zhao J, Ding C, Cramer M, Justen KL, Vonderfecht SL, Na S: Adoptive transfer of in vitro-stimulated CD4+CD25+ regulatory T cells increases bacterial clearance and improves survival in polymicrobial sepsis. J Immunol 2005; 174:7141-6
107. Kühlhorn F, Rath M, Schmoeckel K, Cziupka K, Nguyen HH, Hildebrandt P, Hünig T, Sparwasser T, Huehn J, Pötschke C, Bröker BM: Foxp3+ regulatory T cells are required for recovery from severe sepsis. PLoS One 2013; 8:e65109
108. Kavanagh H, Mahon BP: Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy 2011; 66:523-31
109. Engela AU, Hoogduijn MJ, Boer K, Litjens NH, Betjes MG, Weimar W, Baan CC: Human adipose-tissue derived mesenchymal stem cells induce functional de-novo regulatory T cells with methylated FOXP3 gene DNA. Clin Exp Immunol 2013; 173:343-54
110. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP: Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156:149-60
111. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A: Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107:367-72
112. Liu L HH, Liu A, Xu J, Han J, Chen Q, Hu S, Xu X, Huang Y, Guo F, Yang Y, Qiu H: Therapeutic effects of bone marrowderived mesenchymal stem cells in models of pulmonary and extrapulmonary acute lung injury. Cell Transplant 2015; 24:14
113. Xu G, Zhang L, Ren G, Yuan Z, Zhang Y, Zhao RC, Shi Y: Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Cell Res 2007; 17:240-8
114. Sung DK, Chang YS, Sung SI, Yoo HS, Ahn SY, Park WS: Antibacterial effect of mesenchymal stem cells against Escherichia coli is mediated by secretion of beta- defensin-2 via toll- like receptor 4 signalling. Cell Microbiol 2016; 18:424-36
115. Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Gorham JD, Bundoc VG, Bundoc VG, Hodges MG, Jelinek I, Madala S, Karpati S, Mezey E: Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 2010; 107:5652-7
116. De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F: Immunosuppressive properties of mesenchymal stem cells: Advances and applications. Curr Mol Med 2012; 12:574-91
117. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG: Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007; 104:11002-7
118. Bruno S, Grange C, Collino F, Deregibus MC, Cantaluppi V, Biancone L, Tetta C, Camussi G: Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One 2012; 7:e33115
119. Wang X GH, Qin D, Yang L, Huang W, Essandoh K, Wang Y, Caldwell CC, Peng T, Zingarelli B, Fan GC: Exosomal miR-223 contributes to mesenchymal stem cell-elicited cardioprotection in polymicrobial sepsis. Sci Rep 2015; 5:16
120. Nong K, Wang W, Niu X, Hu B, Ma C, Bai Y, Wu B, Wang Y, Ai K: Hepatoprotective effect of exosomes from humaninduced pluripotent stem cell-derived mesenchymal stromal cells against hepatic ischemia-reperfusion injury in rats. Cytotherapy 2016; 18:1548-59
121. Delarosa O, Dalemans W, Lombardo E: Toll-like receptors as modulators of mesenchymal stem cells. Front Immunol 2012; 3:182
122. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM: A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 2010; 5:e10088
123. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ: Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007; 4:e269
124. He H, Liu L, Chen Q, Liu A, Cai S, Yang Y, Lu X, Qiu H: Mesenchymal stem cells overexpressing angiotensin-converting enzyme 2 rescue lipopolysaccharide-induced lung injury. Cell Transplant 2015; 24:1699-715
125. Zhao YF LY, Xiong W, Ding W, Li YR, Zhao W, Zeng HZ, Gao HC, Wu XL: Mesenchymal stem cell-based FGF2 gene therapy for acute lung injury induced by lipopolysaccharide in mice. Eur Rev Med Pharmacol Sci 2015; 19:9
126. Chen J LC, Gao X, Li C, Liang Z, Yu L, Li Y, Xiao X, Chen L: Keratinocyte growth factor gene delivery via mesenchymal stem cells protects against lipopolysaccharide-induced acute lung injury in mice. PLoS One 2013; 8:11
127. Han J LX, Zou L, Xu X, Qiu H: E-Prostanoid 2 receptor overexpression promotes mesenchymal stem cell attenuated lung injury. Hum Gene Ther 2016; 27:10
128. Cai SX LA, Chen S, He HL, Chen QH, Xu JY, Pan C, Yang Y, Guo FM, Huang YZ, Liu L, Qiu HB: The orphan receptor tyrosine kinase ROR2 facilitates MSCs to repair lung injury in ARDS animal model. Cell Transplant 2016; 25:1561-74
129. Galstian GM, Parovichnikova EN, Makarova PM, Kuzmina LA, Troitskaya VV, Gemdzhian E, Drize NI, Savchenko VG: The results of the Russian clinical trial of mesenchymal stromal cells (MSCs) in severe neutropenic patients (pts) with septic shock (SS) (RUMCESS trial). . Blood 2015; 126:2220
130. Lee ST, Jang JH, Cheong JW, Kim JS, Maemg HY, Hahn JS, Ko YW, Min YH: Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 2002; 118:1128-31
131. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439-41
132. Martin PJ, Uberti JP, Soiffer RJ, Klingemann H, Waller EK, Daly AS, Herrmann RP, Kebriaei P: Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: Results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplantation 2010; 16:S169-S170
133. Le Blanc K, Mougiakakos D: Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012; 12:383-96
134. Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, Bertaina A, Vinti L, Lankester A, Maccario R, Ringden O, Le Blanc K, Egeler RM, Fibbe WE, Locatelli F: Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2011; 46:200-7
135. Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K: Mesenchymal stem cells for treatment of therapy-resistant graft-versushost disease. Transplantation 2006; 81:1390-7
136. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J: Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versushost disease. Biol Blood Marrow Transplant 2009; 15:804-11
137. Galipeau J: The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 2013; 15:2-8
138. Nasseri BA, Ebell W, Dandel M, Kukucka M, Gebker R, Doltra A, Knosalla C, Choi YH, Hetzer R, Stamm C: Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: The Cardio133 trial. Eur Heart J 2014; 35:1263-74
139. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP: A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013; 143:1590-8
140. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-7
141. Lee RH, Hsu SC, Munoz J, Jung JS, Lee NR, Pochampally R, Prockop DJ: A subset of human rapidly self-renewing marrow stromal cells preferentially engraft in mice. Blood 2006; 107:2153-61
142. Reger RL, Prockop DJ: Should publications on mesenchymal stem/progenitor cells include in-process data on the preparation of the cells?. Stem Cells Transl Med 2014; 3:632-5
143. Viswanathan S, Keating A, Deans R, Hematti P, Prockop D, Stroncek DF, Stacey G, Weiss DJ, Mason C, Rao MS: Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells Dev 2014; 23:1157-67
144. Halleux C, Sottile V, Gasser JA, Seuwen K: Multi-lineage potential of human mesenchymal stem cells following clonal expansion. J Musculoskelet Neuronal Interact 2001; 2:71-6
145. Takahashi K, Yamanaka S: A decade of transcription factormediated reprogramming to pluripotency. Nat Rev Mol Cell Biol 2016; 17:183-93
146. Yun YI, Park SY, Lee HJ, Ko JH, Kim MK, Wee WR, Reger RL, Gregory CA, Choi H, Fulcher SF, Prockop DJ, Oh JY: Comparison of the anti-inflammatory effects of induced pluripotent stem cell-derived and bone marrow-derived mesenchymal stromal cells in a murine model of corneal injury. Cytotherapy 2017; 19:28-35
147. Sarugaser R, Hanoun L, Keating A, Stanford WL, Davies JE: Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy. PLoS One 2009; 4:e6498
148. Rubio D, Garcia S, Paz MF, De la Cueva T, Lopez-Fernandez LA, Lloyd AC, Garcia-Castro J, Bernad A: Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS One 2008; 3:e1398
149. François M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J: Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing. Cytotherapy 2012; 14:147-52
150. Alcayaga-Miranda F, Cuenca J, Martin A, Contreras L, Figueroa FE, Khoury M: Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis. Stem Cell Res Ther 2015; 6:199
151. Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzón IM, Nepomnaschy I, Costa H, Cañones C, Raiden S, Vermeulen M, Geffner JR: Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatorylike profile. PLoS One 2010; 5:e9252
152. Gregory CA, Ylostalo J, Prockop DJ: Adult bone marrow stem/progenitor cells (MSCs) are preconditioned by microenvironmental "niches" in culture: A two-stage hypothesis for regulation of MSC fate. Sci STKE 2005; 2005:pe37
153. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J: Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005; 106:4057-65
154. National Institutes of Health. ClinicalTrials.gov. Available at: Https://clinicaltrials.gov. Accessed July 19, 2017.
155. Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX: Toward smarter lumping and smarter splitting: Rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med 2016; 194:147-55
156. Man M, Close SL, Shaw AD, Bernard GR, Douglas IS, Kaner RJ, Payen D, Vincent JL, Fossceco S, Janes JM, Leishman AG, O'Brien L, Williams MD, Garcia JG: Beyond single-marker analyses: Mining whole genome scans for insights into treatment responses in severe sepsis. Pharmacogenomics J 2013; 13:218-26
157. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-64
158. Wong HR, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Willson DF, Freishtat RJ, Anas N, Meyer K, Checchia PA, Monaco M, Odom K, Shanley TP: Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med 2009; 7:34